Search Results 431-440 of 17179 for Botulism

1. Ruxolitinib in Combination with Pemetrexed/Cisplatin in Non Small Cell Lung Cancer - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

2. Identifying Biomarkers for Recurrent CDI and Post-CDI IBS - Mayo Clinic

   difficile infection irritable bowel syndrome. We will study patient characteristics and study stool samples to investigate if bile acid composition, microbiome ...

3. Drugs and Supplements that Start with D - Mayo Clinic

   Explore a comprehensive list of prescription and over-the-counter medications starting with the letter “D” to learn about drug side effects, proper use and ...

4. Lobular carcinoma in situ (LCIS) - Doctors and departments - Mayo Clinic

   If a breast biopsy reveals you have LCIS, your risk of breast cancer is increased. Learn how you can reduce your risk through medications and other ...

5. Gastric fundal mucosal ablation targets hormonal causes of obesity - Mayo Clinic

   Mayo Clinic surgeons pair gastric fundal mucosal ablation with endoscopic sleeve gastroplasty to achieve optimal weight-loss outcomes.

6. Acute Care Learning Laboratory-Reducing Threats to Diagnostic Fidelity in Critical illness - Mayo Clinic

   The purpose of this study is to develop and validate automated phenotypes of diagnostic error and delay that can be applied in near-real time to record medical ...

7. Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma - Mayo Clinic

   Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Drugs used in ...

8. Open-Label Extension Assessing Long Term Safety and Efficacy of ISIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) - Mayo Clinic

   This study evaluates the safety and tolerability of extended dosing with ISIS-TTR Rx in patients with Familial Amyloid Polyneuropathy. Participation eligibility.

9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Mayo Clinic

   A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With ...

10. A Study of HFB200301 in Adult Patients With Advanced Solid Tumors - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...